The choice of target genes was based on our previous observations that GPER mRNA expression did not show any variation between benign, borderline, and malignant ovarian tumour samples [13], whereas uPAR mRNA was higher in borderline and malignant than benign ovarian tumour samples [14]. This evidence concerns the gene PLAUR and ovarian cancer.